KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Ratio (2017 - 2025)

Amneal Pharmaceuticals has reported Equity Ratio over the past 9 years, most recently at 0.02 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.02 for Q4 2025, up 38.32% from a year ago — trailing twelve months through Dec 2025 was 0.02 (up 38.32% YoY), and the annual figure for FY2025 was 0.02, up 38.32%.
  • Equity Ratio for Q4 2025 was 0.02 at Amneal Pharmaceuticals, up from 0.03 in the prior quarter.
  • Over the last five years, Equity Ratio for AMRX hit a ceiling of 0.1 in Q1 2022 and a floor of 0.04 in Q1 2025.
  • Median Equity Ratio over the past 5 years was 0.04 (2023), compared with a mean of 0.03.
  • Biggest five-year swings in Equity Ratio: crashed 641.53% in 2024 and later skyrocketed 38.32% in 2025.
  • Amneal Pharmaceuticals' Equity Ratio stood at 0.09 in 2021, then plummeted by 48.01% to 0.05 in 2022, then plummeted by 88.1% to 0.01 in 2023, then plummeted by 641.53% to 0.03 in 2024, then skyrocketed by 38.32% to 0.02 in 2025.
  • The last three reported values for Equity Ratio were 0.02 (Q4 2025), 0.03 (Q3 2025), and 0.03 (Q2 2025) per Business Quant data.